Company intelligence / Profile preview
Pluvia Biotech
- Ownership
- Private
- Development stage
- Other
Overview
Pluvia Biotech is developing small molecule pharmacological chaperones to treat rare genetic diseases caused by protein misfolding, with a lead program for phenylketonuria (PKU). Their lead compound PBAS499 has received Orphan Drug and Rare Pediatric Disease Designations from the FDA and is progressing toward clinical proof of concept. Preclinical data have been presented at major scientific meetings, and a key patent application has been published[2][7].
- Therapeutic areas
- Metabolic Disorders
- Modalities
- Small moleculePharmacological chaperone
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Pluvia Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pluvia Biotech.